Literature DB >> 9001324

Primary pulmonary hypertension, tissue plasminogen activator antibodies, and HLA-DQ7.

J H Morse1, R J Barst, M Fotino, Y Zhang, E Flaster, A E Gharavi, M J Fritzler, M Dominguez, E Angles-Cano.   

Abstract

Antibodies to fibrin-bound tissue plasminogen activator (tPA) have been found in autoimmune diseases with vascular injury, such as systemic lupus erythematosus and scleroderma. The purpose of this study was to determine whether patients with primary pulmonary hypertension (PPH) have an immunogenetically determined response to fibrin-bound tPA. Antibodies to fibrin-bound tPA were determined in three patient groups: 45 adults with PPH, 41 children with PPH, and 40 children with anatomically large congenital pulmonary to systemic communications (PHT+shunt). The frequencies of the HLA class II (DRB1,3,4,5, and -DQB1) alleles in these three patient groups were compared with those of 51 healthy Caucasian control subjects. Fibrin-bound tPA antibodies were found in four of 45 (9%) adults with PPH, four of 41 (10%) children with PPH, and one of 40 (2.5%) children with PHT-shunt. HLA class II typing, which was available for seven of nine Caucasians with fibrin-bound tPA antibodies, revealed that six of seven (86%) patients typed HLA-DQ7 (DQB1*0301) and one typed HLA-DQ6. The 86% frequency of HLA-DQ7 in the antibody positive patients was significant compared with the 29% frequency in the healthy control subjects (p = 0.007, p corrected [pc] = 0.05, OR = 14.4). Of interest, these antibody-positive patients, although lacking antiphospholipid antibodies, shared an amino acid epitope, common to HLA-DQB1*06,07 and 08 subtypes, which was previously reported to be associated with the lupus anticoagulant. In conclusion, antibodies to fibrin-bound tPA and HLA-DQ7, and possibly the same epitope associated with the lupus anticoagulant, defined a small subset of children and adults with PPH.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9001324     DOI: 10.1164/ajrccm.155.1.9001324

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  12 in total

1.  Anti-topoisomerase II alpha autoantibodies in systemic sclerosis-association with pulmonary hypertension and HLA-B35.

Authors:  B Grigolo; I Mazzetti; R Meliconi; S Bazzi; R Scorza; M Candela; A Gabrielli; A Facchini
Journal:  Clin Exp Immunol       Date:  2000-09       Impact factor: 4.330

2.  Altered immune phenotype in peripheral blood cells of patients with scleroderma-associated pulmonary hypertension.

Authors:  Michael G Risbano; Christina A Meadows; Christopher D Coldren; Tiffany J Jenkins; Michael G Edwards; David Collier; Wendy Huber; Douglas G Mack; Andrew P Fontenot; Mark W Geraci; Todd M Bull
Journal:  Clin Transl Sci       Date:  2010-10       Impact factor: 4.689

Review 3.  Reversible or irreversible remodeling in pulmonary arterial hypertension.

Authors:  Seiichiro Sakao; Koichiro Tatsumi; Norbert F Voelkel
Journal:  Am J Respir Cell Mol Biol       Date:  2009-12-11       Impact factor: 6.914

Review 4.  Systemic sclerosis-associated pulmonary arterial hypertension.

Authors:  Jérôme Le Pavec; Marc Humbert; Luc Mouthon; Paul M Hassoun
Journal:  Am J Respir Crit Care Med       Date:  2010-03-01       Impact factor: 21.405

Review 5.  The role of inflammation and autoimmunity in the pathophysiology of pulmonary arterial hypertension.

Authors:  Nada Kherbeck; Mathieu C Tamby; Guillaume Bussone; Hanadi Dib; Frederic Perros; Marc Humbert; Luc Mouthon
Journal:  Clin Rev Allergy Immunol       Date:  2013-02       Impact factor: 8.667

Review 6.  Genomics of pulmonary arterial hypertension: implications for therapy.

Authors:  Mark W Geraci; Todd M Bull; Rubin M Tuder
Journal:  Heart Fail Clin       Date:  2010-01       Impact factor: 3.179

Review 7.  Pulmonary arterial hypertension in connective tissue diseases.

Authors:  Stephen C Mathai; Paul M Hassoun
Journal:  Heart Fail Clin       Date:  2012-07       Impact factor: 3.179

Review 8.  Immune and inflammatory mechanisms in pulmonary arterial hypertension.

Authors:  Hala El Chami; Paul M Hassoun
Journal:  Prog Cardiovasc Dis       Date:  2012 Sep-Oct       Impact factor: 8.194

9.  Clinical risk factors for portopulmonary hypertension.

Authors:  Steven M Kawut; Michael J Krowka; James F Trotter; Kari E Roberts; Raymond L Benza; David B Badesch; Darren B Taichman; Evelyn M Horn; Steven Zacks; Neil Kaplowitz; Robert S Brown; Michael B Fallon
Journal:  Hepatology       Date:  2008-07       Impact factor: 17.425

10.  HIV protease inhibitors in pulmonary hypertension: rationale and design of a pilot trial in idiopathic pulmonary arterial hypertension.

Authors:  Ying Li; Xiao-Hui Li; Zai-Xin Yu; Jing-Jing Cai; Timothy R Billiar; Alex F Chen; Ben Lv; Zi-Ying Chen; Zhi-Jun Huang; Guo-Ping Yang; Jie Song; Bin Liu; Hong Yuan
Journal:  Pulm Circ       Date:  2015-09       Impact factor: 3.017

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.